Cas:868770-14-3 N-[(4-benzylmorpholin-2-yl)methyl]ethanamine manufacturer & supplier

Chemical Name:N-[(4-benzylmorpholin-2-yl)methyl]ethanamine

CAS.NO:868770-14-3

Synonyms:(4-benzyl-morpholin-2-ylmethyl)-ethyl-amine;AB1160;2-Morpholinemethanamine,N-ethyl-4-(phenylmethyl);N-((4-Benzylmorpholin-2-yl)methyl)ethanamine

Molecular Formula:C₁₄H₂₂N₂O

Molecular Weight:234.33700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:24.50000

Exact Mass:234.17300

LogP:1.82570

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (4-benzyl-morpholin-2-ylmethyl)-ethyl-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-((4-Benzylmorpholin-2-yl)methyl)ethanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,AB1160 Use and application,(4-benzyl-morpholin-2-ylmethyl)-ethyl-amine technical grade,usp/ep/jp grade.

Related News: Like SARS, this latest outbreak is caused by a coronavirus, a family of viruses common to animals that range from the common cold, to more serious diseases, like Middle East respiratory syndrome (MERS). N-[(4-benzylmorpholin-2-yl)methyl]ethanamine manufacturer Russia, which shares a 2,600-mile border with China, reported its first two coronavirus cases on Friday. N-[(4-benzylmorpholin-2-yl)methyl]ethanamine supplier Like SARS, this latest outbreak is caused by a coronavirus, a family of viruses common to animals that range from the common cold, to more serious diseases, like Middle East respiratory syndrome (MERS). N-[(4-benzylmorpholin-2-yl)methyl]ethanamine vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. N-[(4-benzylmorpholin-2-yl)methyl]ethanamine factory Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.